

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 98,429)

PATENT 4.3.00

PATENT 4.3.00

In the Application of:)
Karl W. Hasel and Brian S. Hilbush)
Serial No.: 09/186,869))
Filing Date: November 4, 1998) Group Art Unit: 1643
For: Method for Indexing and Determining The Relative Concentration of Expressed Messenger RNAs	RECEIVED
Dapressed Wessenger MWAS	APR 03 LUULI
Assistant Commissioner for Patents Washington, D.C. 20231	TECH CENTER 1600/2900

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
 - A. Supplemental Information Disclosure Statement;
 - B. Form PTO-1449;
 - C. Copies of seven (7) cited references; and
 - D. Return Receipt Postcard.
- 2. With respect to additional fees, no additional fee is required.
- 3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned also hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231 on this 27th day of March, 2000.

Bv

Koger II. Zimmerman

Reg. No. 38,67

PATENT

\$	
105	
VA = 10	
(O)	27
MAR 3 0 2000	뻥
MAR 3	Ě
1 hrs.	\$
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	> /
PATENT & TRADE	
- ann	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 98,429)

In re	Application of:)	
)	
	Karl W. Hasel and Brian S. Hilbush)	
)	
Serial	No.: 09/186,869)	
)	Group Art Unit: 1643
Filed:	November 4, 1998)	
)	
For:	METHOD FOR INDEXING AND)	
	DETERMINING THE RELATIVE)	
	CONCENTRATION OF EXPRESSED)	
	MESSENGER RNA'S)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449 and copies of the documents listed thereon. These documents contain information that the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

FOREIGN PATENT DOCUMENTS

- 1. WO 95/13369
- 2. WO 93/18176
- 3. WO 97/29211

OTHER DOCUMENTS

- 4. Stratagene Catalogue XP002132253, pages 23 and 39 (1997).
- 5. Ayala, M., et al., New Primer Strategy Improves Precision of Differential Display, Biotechniques, 18: (5) 842-850, January 1, 1995.
- 6. Jones, S. W., et al., Generation of Multiple mRNA Fingerprints Using Fluorescence-Based Differential Display and an Automated DNA Sequencer, <u>Biotechniques</u>, 22: (3) 536-543, March 1997.
- 7. International Search Report for Application No. PCT/US99/23655, dated March 6, 2000.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No

representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: March 27, 2000

Roger P. Zimmerman Registration No. 38,670